Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy

BACKGROUND: ONC201, a dopamine receptor D2 (DRD2) antagonist and caseinolytic protease P (ClpP) agonist, has induced durable tumor regressions in adults with recurrent H3 K27M-mutant glioma. We report results from the first phase I pediatric clinical trial of ONC201. METHODS: This open-label, multi-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Sharon L, Tarapore, Rohinton S, Allen, Jeffrey, McGovern, Susan L, Zaky, Wafik, Odia, Yazmin, Daghistani, Doured, Diaz, Zuanel, Hall, Matthew D, Khatib, Ziad, Koschmann, Carl, Cantor, Evan, Kurokawa, Ryo, MacDonald, Tobey J, Aguilera, Dolly, Vitanza, Nicholas A, Mueller, Sabine, Kline, Cassie, Lu, Guangrong, Allen, Joshua E, Khatua, Soumen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639395/
https://www.ncbi.nlm.nih.gov/pubmed/36382108
http://dx.doi.org/10.1093/noajnl/vdac143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639395/
https://www.ncbi.nlm.nih.gov/pubmed/36382108
http://dx.doi.org/10.1093/noajnl/vdac143

Ejemplares similares